Incyte Genomics (INCY) Misses Q2 Views
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 11/1/2026
- Wall Street closes sharply lower as AI cash burn fears spark tech selloff
- Amazon burns cash, Intel flags weak PC demand as AI boom's costs ripple across markets
- Bitcoin, cryptocurrency prices fall after Binance reports security issue
- Higher yields now hurting AI stock bull as bond markets police capex: BofA
- Oil jumps 2%, settles at 6-month highs on fears of escalation in Iran
Tweet
Share
E-mailGet Alerts INCY Hot Sheet
Price: $120.39 +3.07%
Financial Fact:
Basic (in dollars per share): 0.2
Today's EPS Names:
OPY, BNCC, ZVOI, More
Financial Fact:
Basic (in dollars per share): 0.2
Today's EPS Names:
OPY, BNCC, ZVOI, More
Join SI Premium – FREE
Incyte Genomics (NASDAQ: INCY) reported Q2 EPS of ($0.41), $0.05 worse than the analyst estimate of ($0.36). Revenue for the quarter came in at $16.8 million versus the consensus estimate of $19.17 million.
Serious News for Serious Traders! Try StreetInsider.com Premium Free!
You May Also Be Interested In
- Incyte (INCY) PT Raised to $117 at RBC Capital
- Aurinia Pharmaceuticals (AUPH) Misses Q3 EPS by 1c, Misses on Revenue; Offers FY26 Revenue Guidance
- Oppenheimer Upgrades Incyte (INCY) to Outperform
Create E-mail Alert Related Categories
EarningsSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
